Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · THEMIS MEDICARE LTD. · 22 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
THEMIS MEDICARE LTD.
NSE: THEMISMED · BSE: 530199
NSE: THEMISMED · BSE: 530199
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
THEMIS MEDICARE LTD.
StateQ1 FY27 filed
Last close · 20 Sept 2026₹124.00
Market cap₹1.1k cr
TTM P/E · P/B · EV/EBITDA28.6 · 2.87 · 20.9
THEMIS MEDICARE LTD. is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 395 | 354 | 382 | 406 | 342 |
| EBITDA (ex other income) | 96 | 67 | 52 | 49 | (0) |
| margin % | 24.2 | 19.0 | 13.5 | 12.1 | (0.1) |
| Owners' profit | 73 | 57 | 44 | 30 | 1 |
| EPS, as reported (₹) | 79.22 | 61.83 | 4.73 | 3.24 | 0.12 |
| ROE % · ROCE % | 25.4 · 29.1 | 16.8 · 18.3 | 11.5 · 10.7 | 7.4 · 10.1 | 0.3 · (0.3) |
| Debt / equity (x) | 0.27 | 0.27 | 0.25 | 0.21 | 0.25 |
| Cash from operations | 34 | 16 | 14 | 35 | (3) |
| Capex | (20) | (29) | (18) | (15) | (5) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · THEMIS MEDICARE LTD. · 22 September 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 117 | 94 | 72 | 98 | 78 | 90 | 77 | 87 |
| Profit before tax | 13 | 4 | (9) | (14) | (5) | 5 | 2 | 36 |
| Net profit | 14 | 1 | (10) | (14) | (4) | 10 | 9 | 25 |
| EPS (₹) | 1.55 | 0.06 | (1.05) | (1.54) | (0.39) | 1.10 | 0.96 | 2.67 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,49,869 | 37.2 | 5.36 | 24.1 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,49,683 | 85.5 | 14.90 | 64.4 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,282 | 79.4 | 9.57 | 41.6 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,16,367 | 26.0 | 3.93 | 15.0 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,11,403 | 33.0 | 3.23 | 17.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,08,995 | 99.6 | 20.07 | 60.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| MANKIND PHARMA LIMITED | 1,00,400 | 49.1 | 6.06 | 27.6 | 11.7 | 10.8 | — | 27.3 |
| DR. REDDY S LABORATORIES | 1,00,367 | 31.1 | 2.63 | 13.5 | 10.9 | 13.0 | 12.1 | 15.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 28.6 | 29.6 | 84 of 170 | 51% |
| P/B | 2.9 | 3.3 | 75 of 164 | 55% |
| ROCE | (2.8) | 10.8 | 160 of 183 | 13% |
| ROE | 0.3 | 10.4 | 145 of 171 | 15% |
| Debt / Equity | 0.3 | 0.1 | 110 of 171 | 36% |
| EBITDA margin | 47.8 | 17.5 | 5 of 165 | 98% |
| Revenue growth | (10.9) | 16.3 | 134 of 161 | 17% |
| Profit growth | 273.1 | 30.9 | 20 of 158 | 88% |
| Market cap | 1142 | 770 | 87 of 184 | 53% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · THEMIS MEDICARE LTD. · 22 September 2026Page 3 of 3
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 18 Sept 2026 · Record date fixed for FY26 final dividend | corporate actions | high | — | — |
| 9 Sept 2026 · AGM notice published; 56th AGM set for 30 Sep 2026 | compliance | minimal | — | — |
| 8 Sept 2026 · Themis Medicare 56th AGM notice on Sep 30, 2026; dividend proposed | board shareholder meetings | low | — | — |
| 8 Sept 2026 · Notice of 56th AGM and Annual Report for FY 2025-26 | board shareholder meetings | medium | — | — |
| 8 Sept 2026 · Themis Medicare files FY26 Annual Report, 56th AGM on 30 Sept 2026 | board shareholder meetings | medium | — | — |
| 8 Sept 2026 · Themis Medicare 56th AGM Notice and Annual Report FY 2025-26 | board shareholder meetings | medium | — | — |
| 7 Sept 2026 · Clarification on unusual trading volume — no pending disclosures | regulatory legal | medium | — | — |
| 7 Sept 2026 · NSE flags unusual trading volume in Themis Medicare; seeks clarification | compliance | medium | — | — |
| 17 Aug 2026 · Update of Company Secretary email ID and RTA email ID | compliance | minimal | — | — |
| 14 Aug 2026 · Newspaper publication of Q1 FY27 financial results | compliance | minimal | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in